ஓலேஃப் வால்டர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஓலேஃப் வால்டர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஓலேஃப் வால்டர் Today - Breaking & Trending Today
Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
L'engagement continu d'Octapharma à améliorer la vie des personnes atteintes d'hémophilie et de la maladie de von Willebrand sera mis en vedette lors du congrès ISTH 2021. prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Adopt-A-Pet Tuesday: Caesar, Olaf & Walter 9and10news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 9and10news.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq ....
22 febbraio 2021 17:11 Fonte: Adnkronos #chimica-e-farmacia - LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 1 ....